These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35780320)

  • 1. Histologic response to steroids in eosinophilic esophagitis is dependent on delivery compound.
    Schupack DA; Johnson K; Akambase JA; Geno D; Lavey C; Lennon RJ; Ravi K; Snyder DL; Katzka DA; Alexander JA
    Dis Esophagus; 2022 Dec; 36(1):. PubMed ID: 35780320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of Fluticasone to Budesonide in the Treatment of Eosinophilic Esophagitis.
    Albert D; Heifert TA; Min SB; Maydonovitch CL; Baker TP; Chen YJ; Moawad FJ
    Dig Dis Sci; 2016 Jul; 61(7):1996-2001. PubMed ID: 27093866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent insights on the use of topical steroids in eosinophilic esophagitis.
    Reddy A; Ashat D; Murali AR
    Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):953-963. PubMed ID: 32567417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Comparison of Fluticasone Propionate and Oral Viscous Budesonide in Children With Eosinophilic Esophagitis.
    Fable JM; Fernandez M; Goodine S; Lerer T; Sayej WN
    J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):26-32. PubMed ID: 28489670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of budesonide vehicles in inducing histologic remission in pediatric eosinophilic esophagitis.
    Lendner N; Minich NM; Malay S; Sferra TJ; Young DD
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):92-99. PubMed ID: 38803200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
    Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
    Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical steroids in eosinophilic esophagitis: Systematic review and meta-analysis of placebo-controlled randomized clinical trials.
    Murali AR; Gupta A; Attar BM; Ravi V; Koduru P
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1111-9. PubMed ID: 26699695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution manometry in patients with eosinophilic esophagitis under topical steroid therapy-a prospective observational study (HIMEOS-study).
    Nennstiel S; Bajbouj M; Becker V; Slotta-Huspenina J; Wagenpfeil S; Schmid RM; Schlag C
    Neurogastroenterol Motil; 2016 Apr; 28(4):599-607. PubMed ID: 26891170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Every-other-day Dosing of Oral Viscous Budesonide Is not Effective in the Management of Eosinophlic Esophagitis.
    Rubinstein E; Hait EE; Mitchell PD; Lee JJ
    J Pediatr Gastroenterol Nutr; 2018 Mar; 66(3):395-397. PubMed ID: 28837508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis.
    Runge TM; Eluri S; Woosley JT; Shaheen NJ; Dellon ES
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 29206905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis.
    Straumann A; Conus S; Degen L; Frei C; Bussmann C; Beglinger C; Schoepfer A; Simon HU
    Clin Gastroenterol Hepatol; 2011 May; 9(5):400-9.e1. PubMed ID: 21277394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
    Dellon ES; Woosley JT; Arrington A; McGee SJ; Covington J; Moist SE; Gebhart JH; Tylicki AE; Shoyoye SO; Martin CF; Galanko JA; Baron JA; Shaheen NJ
    Gastroenterology; 2019 Jul; 157(1):65-73.e5. PubMed ID: 30872104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients.
    Wolf WA; Cotton CC; Green DJ; Hughes JT; Woosley JT; Shaheen NJ; Dellon ES
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):452-8. PubMed ID: 25086190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence?
    Walgraeve S; Vanuytsel T
    Acta Gastroenterol Belg; 2023; 86(3):437-448. PubMed ID: 37814560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice.
    Laserna-Mendieta EJ; Casabona S; Savarino E; Perelló A; Pérez-Martínez I; Guagnozzi D; Barrio J; Guardiola A; Asensio T; de la Riva S; Ruiz-Ponce M; Rodríguez-Oballe JA; Santander C; Arias Á; Lucendo AJ;
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2903-2911.e4. PubMed ID: 31988045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.
    Collins MH; Dellon ES; Katzka DA; Hirano I; Williams J; Lan L
    Am J Surg Pathol; 2019 Nov; 43(11):1501-1509. PubMed ID: 31498177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
    Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
    Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real-world efficacy from the EoE CONNECT registry.
    Laserna-Mendieta EJ; Navarro P; Casabona-Francés S; Savarino EV; Amorena E; Pérez-Martínez I; Guagnozzi D; Blas-Jhon L; Betoré E; Guardiola-Arévalo A; Pellegatta G; Krarup AL; Perello A; Barrio J; Gutiérrez-Junquera C; Teruel Sánchez-Vegazo C; Fernández-Fernández S; Naves JE; Oliva S; Rodríguez-Oballe JA; Carrión S; Espina S; Llorente Barrio M; Masiques-Mas ML; Dainese R; Feo-Ortega S; Martín-Dominguez V; Fernández-Pacheco J; Pérez-Fernández MT; Ghisa M; Maniero D; Nantes-Castillejo Ó; Nicolay-Maneru J; Suárez A; Maray I; Llerena-Castro R; Ortega-Larrodé A; Alcedo J; Granja Navacerrada A; Racca F; Santander C; Arias Á; Lucendo AJ;
    United European Gastroenterol J; 2024 Jun; 12(5):585-595. PubMed ID: 38284792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histologic and Clinical Effects of Different Topical Corticosteroids for Eosinophilic Esophagitis: Lessons from an Updated Meta-Analysis of Placebo-Controlled Randomized Trials.
    de Heer J; Miehlke S; Rösch T; Morgner A; Werner Y; Ehlken H; Becher H; Aigner A
    Digestion; 2021; 102(3):377-385. PubMed ID: 32610332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.
    Gupta SK; Vitanza JM; Collins MH
    Clin Gastroenterol Hepatol; 2015 Jan; 13(1):66-76.e3. PubMed ID: 24907502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.